Article
CRO Inotiv continues M&A strategy with $11M Protypia buy
Rating:
0.0
Views:
38
Likes:
1
Library:
1
Buying Protypia will help cater to the growing demand for bioanalytical services in the discovery lab and beyond, says Inotiv. | The non-clinical CRO announced the $11 million acquisition of Tennessee-based Protypia last week, citing its capabilities in protein bioanalysis and tissue-based protein and peptide mass spectrometry as the motivation for the deal.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value